Roth Capital Analysts Lift Earnings Estimates for Longeveron

Longeveron Inc. (NASDAQ:LGVN) – Equities researchers at Roth Capital raised their Q1 2025 earnings per share estimates for shares of Longeveron in a research report issued on Monday, March 3rd. Roth Capital analyst B. Pachaiyappan now forecasts that the company will post earnings of ($0.30) per share for the quarter, up from their prior estimate of ($0.36). Roth Capital currently has a “Strong-Buy” rating on the stock. The consensus estimate for Longeveron’s current full-year earnings is ($3.69) per share. Roth Capital also issued estimates for Longeveron’s Q2 2025 earnings at ($0.33) EPS, Q3 2025 earnings at ($0.37) EPS and FY2025 earnings at ($1.40) EPS.

LGVN has been the subject of a number of other reports. Roth Mkm began coverage on Longeveron in a research note on Friday, December 6th. They set a “buy” rating and a $10.00 price objective for the company. HC Wainwright reiterated a “buy” rating and set a $10.00 target price on shares of Longeveron in a research report on Monday.

Longeveron Trading Up 5.3 %

Shares of NASDAQ:LGVN opened at $1.40 on Thursday. The stock has a 50 day moving average of $1.64 and a 200 day moving average of $1.89. The company has a market cap of $20.77 million, a PE ratio of -0.22 and a beta of 0.36. Longeveron has a 12-month low of $0.77 and a 12-month high of $6.40.

Institutional Trading of Longeveron

Several hedge funds and other institutional investors have recently bought and sold shares of LGVN. State Street Corp purchased a new stake in Longeveron during the 3rd quarter valued at $29,000. Northern Trust Corp purchased a new stake in Longeveron in the fourth quarter worth $31,000. Jane Street Group LLC purchased a new position in shares of Longeveron during the fourth quarter valued at $35,000. Virtu Financial LLC purchased a new position in shares of Longeveron during the fourth quarter valued at $53,000. Finally, Geode Capital Management LLC increased its stake in shares of Longeveron by 316.0% during the third quarter. Geode Capital Management LLC now owns 128,947 shares of the company’s stock valued at $250,000 after buying an additional 97,953 shares during the period. Hedge funds and other institutional investors own 10.01% of the company’s stock.

Longeveron Company Profile

Longeveron Inc, a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company’s lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors.